Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective Subendothelial LDL retention by intimal matrix proteoglycans is an initial step in atherosclerosis and calcific aortic valve disease. Herein, we identify decorin and biglycan as the proteoglycans that preferentially retain LDL in intimal matrix at disease-prone sites in normal valve and vessel wall. Methods The porcine aortic valve and renal artery ostial diverter, initiation sites of calcific valve disease and renal atherosclerosis, respectively, from normal non-diseased animals were used as models in these studies. Results Fluorescent human LDL was selectively retained on the lesion-prone collagen/proteoglycan-enriched aortic surface of the valve, where the elastic lamina is depleted, as previously observed in lesion-prone sites in the renal ostium. iTRAQ mass spectrometry of valve and diverter protein extracts identified decorin and biglycan as the major subendothelial intimal matrix proteoglycans electrostatically retained on human LDL affinity columns. Decorin levels correlated with LDL binding in lesion-prone sites in both tissues. Collagen binding to LDL was shown to be proteoglycan-mediated. All known basement membrane proteoglycans bound LDL suggesting they may modulate LDL uptake into the subendothelial matrix. The association of purified decorin with human LDL in an in vitro microassay was blocked by serum albumin and heparin suggesting anti-atherogenic roles for these proteins in vivo. Conclusions LDL electrostatic interactions with decorin and biglycan in the valve leaflets and vascular wall is a major source of LDL retention. The complementary electrostatic sites on LDL or these proteoglycans may provide a novel therapeutic target for preventing one of the earliest events in these cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 1×
“Valvular calcific disease is associated with elevated plasma LDL levels [10,11] and lowering plasma cholesterol has been shown to halt the progression of aortic valve disease in amousemodel [12].”
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Otagiri, M., & Curry, S. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.075 · Cited by 1,941 · cited 1×
“Exposed Lys 195 and Lys 199 [41,42] on the albumin molecule may be responsible for the interaction with decorin, consistent with the well characterized electrostatic interactions of albumin with numerous plasma proteins and drugs [43].”
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019 · cited 1×
“What might be the best target for interfering with the electrostatic interaction between LDL lysines and the decorin and biglycan glycans in disease-prone cardiovascular sites? In vivo validation for this therapeutic approach has in part been provided by studies which showed that mutations in the proteoglycan binding…”
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842
O’Brien, K. D., Reichenbach, D. D., Marcovina, S. M., Kuusisto, J., Alpers, C. E., & Otto, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.4.523 · Cited by 560
A model of tenascin-X integration within the collagenous network
Lethias, C., Carisey, A., Comte, J., Cluzel, C., & Exposito, J.-Y. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.10.037 · Cited by 74
Antiatherosclerotic Effect of an Antibody That Binds to Extracellular Matrix Glycosaminoglycans
Soto, Y., Acosta, E., Delgado, L., Pérez, A., Falcón, V., Bécquer, M. A., Fraga, Á., Brito, V., Álvarez, I., Griñán, T., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.238659 · Cited by 41 · cited 1×
“What might be the best target for interfering with the electrostatic interaction between LDL lysines and the decorin and biglycan glycans in disease-prone cardiovascular sites? In vivo validation for this therapeutic approach has in part been provided by studies which showed that mutations in the proteoglycan binding…”
Cited by
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Toll-like Receptors in the Vascular System: Sensing the Dangers Within
Goulopoulou, S., McCarthy, C. G., & Webb, R. C. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.010090 · Cited by 263
Schlotter, F., Halu, A., Goto, S., Blaser, M. C., Body, S. C., Lee, L. H., Higashi, H., DeLaughter, D. M., Hutcheson, J. D., Vyas, P., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032291 · Cited by 256
Mathieu, P., Bossé, Y., Huggins, G. S., Corte, A. D., Pibarot, P., Michelena, H. I., Limongelli, G., Boulanger, M., Evangelista, A., Bédard, E., et al. (2015) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.21 · Cited by 76
Proteomic architecture of valvular extracellular matrix
Bouchareb, R., Guauque-Olarte, S., Snider, J., Zaminski, D., Anyanwu, A., Stelzer, P., & Lebeche, D. (2021) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.11.008 · Cited by 52
“Indeed, proteoglycan accumulations promote lipoprotein retention (23), such as oxidized LDL, which is a key stimulator of cell mineralization through the activation of an inflammatory response (36,37).”
BackgroundInfluential
Metadata
- Authors
- Neufeld, E. B., Zadrozny, L. M., Phillips, D., Aponte, A., Yu, Z.-X., & Balaban, R. S.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 233
- Issue
- 1
- Pages
- 113-121
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2056879293
- Cited by
- 51
- References
- 9
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2013.12.038
- The paper
- Neufeld, E. B., Zadrozny, L. M., Phillips, D., Aponte, A., Yu, Z.-X., & Balaban, R. S. (2014). Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2013.12.038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.